Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Impact · against what's priced in

The presentation of biomarker data for botensilimab and balstilimab provides positive clinical evidence for the company's lead candidates in cold tumors. While translational data is generally a positive sign for biotech valuation, it remains early-stage Phase 1b data rather than a definitive catalyst for commercialization.

AGEN+0.30

No priced-in read yet